Evidence map›Paper›PMID 40670728›Full record

ArticleAnnals of hematology2025

Consequences and impacts of PEG-IFNα2a shortage: first lessons from a MPN French center.

Laura Cailly, Wayne-Corentin Lambert, Jean-Richard Eveillard, Brigitte Pan-Petesch, Laura Herbreteau, Laetitia Rio, Lanig Civi, Adrian Tempescul, Florence Dalbies, Hussam Saad and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Laura CaillyService d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France.
Wayne-Corentin LambertLaboratoire d'Hématologie, CHU de Brest, Brest, France.
Jean-Richard EveillardService d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France.
Brigitte Pan-PeteschService d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France.
Laura HerbreteauService d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France.
Laetitia RioService d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France.
Lanig CiviService d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France.
Adrian TempesculService d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France.
Florence DalbiesService d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France.
Hussam SaadService d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France.
Cristina BagaceanService d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France.
Marie-Anne CouturierService d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France.
Gaelle GuillermService d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France.
Eric Lippert *Laboratoire d'Hématologie, CHU de Brest, Brest, France.
Jean-Christophe Ianotto *Service d'Hématologie et d'Hémostase Clinique, Hôpital de la Cavale Blanche, CHU de Brest, Bld Tanguy Prigent, Brest cedex, 29609, France. jean-christophe.ianotto@chu-brest.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Between March to December 2024, we observed a PEG-IFNα2a shortage in France for MPN patients. We identified and followed 90 patients from our center and observed 80% of difficulties obtaining the drug, and 61 patients among all (67.8%) did not receive their prescribed drug on time (impacted group). Twenty-one patients need to reduce the dosage of PEG-IFNα2a and 27 stopped the drug. Ten clinical events were identified with nine in the impacted group (p=0.04). No hematological or only partial responses were more frequent in the impacted group (p=0.01). The allelic burden variations were also studied during this period; 17 patients obtained a VAF <10%. Eight patients stopped the drug because of VAF <4% and remained with molecular response. Three-quarters of the patients experimented with psychological and financial impacts of shortage. This study is the first one to explore a shortage of cytoreductive drugs happened in MPN. Much informations will be helpful for clinicians.

Indexed as

Interferon-alphaMyeloproliferative DisordersPolyethylene GlycolsAdultAgedAged, 80 and overFemaleFranceHumansMaleMiddle AgedRecombinant ProteinsRetrospective StudiesInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsMyeloproliferative neoplasmsOutcomesPEG-IFNα2aShortage

Identifiers

PMID40670728
PMCPMC12432018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.